Kornimate/medical-research-clean huggingface dataset:
the intraocular pressure measured by different tonometers in corneal edema

Conditions: Intraocular Pressure; Corneal Edema

Summary: the investigators conduct this study to access the effect of corneal edema (the investigators are particularly interested in those who have the clinical central corneal edema) on the variation of intraocular pressure values measured by 3 commercial-available tonometers compare to the current gold standard tonometer; goldmann applanation tonometer.

previous published articles reported on the effect of corneal edema on the accuracy of tonometry were performed in enucleated cadaver eyes, or contact lens-induced corneal edema eyes. thus, it remains unclear as to how the clinical corneal edema that is found in routine clinical practice will affect the variation of intraocular pressure measurement using the standard goldmann applanation tonometer and other more modern tonometers such as the dynamic contour tonometer, the icare, and the tonopen.

Eligibility criteria:
inclusion criteria: * age more than 18 year-old * patients who have a clinical central corneal edema after clear cornea phacoemulsification and intraocular lens implantation * agree to participate in the study and willing to sign an informed consent exclusion criteria: * combined phacoemulsification and trabeculectomy * clear cornea phacoemulsification that has suture on the cornea * previous history of intraocular surgery, ocular trauma prior to phacoemulsification * vitrectomized eye * history of glaucoma or ocular hypertension or using iop lowering medication * history of diabetic retinopathy staged as severe non-proliferative or worse * pregnant or breast-feeding women * history of refractive surgery or any keratoplastic procedure * corneal opacities or diseases making no suitable tonometry * severe dry eye syndrome * wears contact lenses * astigmatism higher than 2.5 diopters * microphthalmos or buphthalmos * subjects with having poor or eccentric fixation or nystagmus * excessive eye squeezing * known allergy to topical anesthesia * known allergy to fluorescein solution

Keywords: intraocular pressure corneal edema tonometer dynamic contour tonometer tonopen icare goldmann applanation
study of chronic exposure of the population living on the atlantic coast and on the caribbean coast, in martinique, during the stranding period and outside the stranding period of sargassum seaweeds

Conditions: Obstructive Ventilatory Disorders

Summary: sargassum are pelagic brown sea algae. two species grow on the surface of the ocean and drift freely with ocean currents in the form of slicks: the pelagic sargassum fluitans and sargassum natans. since 2011, massive strandings of sargassum seaweed in the french west indies are to be deplored. in recent years, strandings have increased. in martinique, sargassum stranding occurs mainly on the atlantic coast. the duration of stranding from one year to another is variable, but the period during which the stranding is maximum is between april and october. the accumulation of strandings causes the compaction of algae and limits access to oxygen, which leads to anaerobic degradation which quickly results in the release of various gases, in particular hydrogen sulphide (h2s). acute h2s poisoning is well characterized clinically according to exposure (cutaneous, respiratory, ophthalmological, digestive, neurological symptoms, etc.). on the other hand, there are very few data available on the clinical effects of prolonged, repeated exposure and most often at low doses. among the toxic effects for which there are still uncertainties regarding long-term exposure to h2s are lung function, measured by spirometry, and airway inflammation, appreciable by measurement of feno (fractional exhaled nitric oxide). the investigators consider it relevant to focus on the clinical and biological characteristics of the population exposed to sargassum in martinique, in the field, assuming that exposure to sargassum h2s causes pulmonary effects measurable by spirometry and by feno, during the stranding period and outside this period.


Eligibility criteria:
inclusion criteria: * adult participant (age greater than or equal to 18), * participant living on the atlantic coast in martinique, close (less than 300 meters) to sargassum seaweed stranding areas (exposed group), * participant living on the caribbean coast, in martinique (unexposed group), * participant having been informed of the research, * participant having given his free, informed and express consent, * participant affiliated to a social security scheme. exclusion criteria: * minor participant, * participant with a known respiratory or cardiac pathology, * participant with a cognitive state that does not allow him to answer the questionnaire, * participant who refused to participate in the study, * pregnant or breastfeeding women.

Keywords: sargassum seaweed exposure to h2s pulmonary effects h2s poisoning fractional exhaled nitric oxide spirometry
pilot study of pancreatic cancer screening

Conditions: Pancreatic Carcinoma

Summary: this study investigates how often abnormal findings from routine magnetic resonance imaging occur in people with genetic mutations in breast cancer gene. (brca), ataxia telangiectasia mutated gene (atm), or palb2 screened for pancreatic cancer. this study may lead to a greater understanding of cancer and potentially, improvements in cancer screening and treatment.

primary objective: i. to determine the event rate of abnormal magnetic resonance imaging (mri) and endoscopic ultrasound (eus) findings in screened study participants. secondary objectives: i. to determine the rates of high-grade pancreatic neoplasia precursors (intraductal papillary mucinous neoplasm (ipmn)-high-grade dysplasia (hgd)) and pancreatic intraepithelial neoplasia-3 \[panin-3\]) and pancreatic ductal adenocarcinoma (pdac) among all study participants. ii. to understand rates of procedures (biopsies and surgeries) among all study participants. exploratory objectives: i. to create a biorepository of all participants through the collection of saliva, blood, and tissue, combined with imaging findings and robust clinical annotation of patient health behaviors in all study participants. ii. to explore knowledge, attitudes, and anxiety related to pancreatic cancer screening at annual intervals in all study participants. outline: participants are assigned to 1 of 2 groups. group i: group i: participants may opt to undergo mri/magnetic resonance cholangiopancreatography (mrcp) or alternating mri/mrcp and eus annually for 10 years or complete questionnaires over 10 minutes and undergo blood, saliva and tissue sample collection. group ii: participants may undergo mri/mrcp or alternating mri/mrcp and eus annually for 10 years.

Eligibility criteria:
inclusion criteria: ability to provide consent and willing, and able to comply with study procedures ability to read and speak english group i: * documentation of pathogenic or likely pathogenic germline brca 1 and 2, atm or palb2 germline genetic mutation * no strong family history of pancreatic cancer (defined as having \>= 1 first-degree or second-degree relative with a history of pancreatic cancer) * age \>= 50 years old at time of consent. group ii: * documentation of pathogenic or likely pathogenic germline brca 1 and 2, atm, or palb2 germline genetic mutation * has strong family history of pancreatic cancer (defined as having \>= 1 first-degree or second-degree relative with a history of pancreatic cancer) * age \>= 18 years old at time of consent (screening generally begins 10 years prior to the earliest pancreatic cancer in the family) exclusion criteria: * prior or active pancreatic cancer. * pregnant women are excluded from this study because effects of an mri on developing fetus is unknown.
an ovarian, primary peritoneal or fallopian tube cancer study for patients that have not received prior chemotherapy

Conditions: Genital Neoplasms, Female; Fallopian Tube Neoplasms; Ovarian Neoplasms; Pelvic Neoplasms; Peritoneal Neoplasms

Summary: this is a phase iii randomized study comparing induction treatments of gemcitabine and carboplatin versus paclitaxel and carboplatin, with or without consolidation therapy for patients that do not have any evidence of disease after completion of six cycles of induction therapy. patients with disease after induction therapy will crossover to receive single agent therapy.

this study (study b9e-us-s302) is a multicenter, comparative, open-label randomized, superiority, trial evaluating gemcitabine and carboplatin to the standard of care. both treatment arms will be given the option to receive elective consolidation therapy of paclitaxel 135 mg/m\^2 given every 28 days for one year. patients not achieving a complete response will crossover to the opposite single agent.

Eligibility criteria:
key inclusion criteria: * patients with a histologic diagnosis of primary peritoneal carcinoma, epithelial ovarian carcinoma or fallopian tube carcinoma stage ic, ii, iii or iv. * all patients must have had surgery for fallopian, ovarian or peritoneal carcinoma to establish the diagnosis and have tissue available for histologic evaluation and confirmation of organ of origin. * patients must be enrolled no more than twelve weeks postoperatively. * patients must be willing to receive their chemotherapy drugs intravenously, as intraperitoneal therapy is not part of this trial. key exclusion criteria: * patients with a current diagnosis of epithelial ovarian tumor of low malignant potential (borderline carcinomas) are not eligible. * patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded * patients who have received prior chemotherapy for any abdominal or pelvic tumor are excluded * with the exception of non-melanoma skin cancer and other specific malignancies patients who had (or have) any evidence of the other cancer present within the last 5 years or whose previous cancer treatment contraindicates this protocol therapy are excluded.
functionality and family characteristics in children with cerebral palsy

Conditions: Cerebral Palsy; Family Characteristics

Summary: the aim of this study was to investigate the effect of family characteristics on functional level in children with spastic type cerebral palsy who are able to walk.


Eligibility criteria:
inclusion criteria: * diagnosed with hemiparetic and diparetic type cp * between the ages of 5-15 * gmfcs level i, ii and iii * volunteer individuals were included. exclusion criteria: * having undergone a surgical operation within the last year, * having contracture in the lower extremity, * having had a fracture in the lower extremity in the last 6 months, * botulinum toxin a (btx-a) administered in the last 6 months * patients with cognitive, visual or hearing impairments that would prevent communication with their peers and siblings were excluded from the study.

Keywords: functional level
use of low-dose zolpidem in parkinson's disease

Conditions: Parkinson Disease

Summary: this study will evaluate the motor and cognitive benefits of low-dose zolpidem in parkinson's.

zolpidem is a hypnotic drug which at sub-sedative doses has been shown to improve both motor and cognitive deficits in stroke, dementia and parkinson's. this has led to the hypothesis that low-dose zolpidem will be effective in early-stage parkinson's, delaying the need for dopamine-replacement interventions, as an adjunct therapy, and in late-stage parkinson's where current interventions are ineffective for motor and cognitive decline. at present, the symptoms of late-stage parkinson's are the most debilitating and the least well-controlled. here, the investigators propose a placebo controlled double-blinded proof-of-concept study in order to determine the benefits of taking low-dose zolpidem in late-stage parkinson's. the study will take place over 12 months. 28 participants, diagnosed with parkinson's for at least 5 years will be recruited; 14 participants will take zolpidem (5 mg) and 14 placebo, each morning for 4 days. in the clinic (day 1) clinical assessments will include the motor iii of the unified parkinson's disease rating scale (updrs) and cognitive verbal fluency tasks which will be conducted at baseline and 1 hour following drug administration. each participant will then be issued with a smartphone with application to objectively test their motor performance 4 times a day, over the next six days (3 days on drug, 3 days off drug). this study will provide the necessary data on drug efficacy in order to design a phase ii clinical trial for the use of low-dose zolpidem in late-stage parkinson's.

Eligibility criteria:
inclusion criteria: diagnosis of idiopathic parkinson's and hoehn and yahr score of 2.5 or more; willing to participate and refrain from driving whist taking zolpidem/placebo; within age range 40 to 80 years. exclusion criteria: any contraindications as stated in summary of product characteristics (smpc) for zolpidem:- hypersensitivity to zolpidem tartrate; obstructive sleep apnoea; myasthenia gravis; severe hepatic insufficiency; acute and/or severe respiratory depression; psychotic illness. and in addition: - unable or unwilling to give informed consent ; current therapy with central nervous system (cns) depressants; current therapy with cytochrome p450 (cpy450) inhibitors or inducers (specifically cyp3a4); pregnancy and breast feeding women; history of alcohol or substance abuse; employed in a role that involves driving or operating heavy machinery; participation in another interventional clinical trial.

Keywords: motor; cognition
a post market cohort with the spinal modulation neurostimulator system in peripheral neuropathy

Conditions: Peripheral Neuropathy

Summary: 10-smi-2012 is a post market observational, questionnaire based study to assess the effectiveness of the commercially available axium neurostimulator in the management of peripheral neuropathy


Eligibility criteria:
inclusion criteria: 1. subject is at least 18 years old 2. subject is able and willing to comply with the follow-up schedule and protocol 3. peripheral neuropathy for at least 6 months 4. failed conservative treatments for chronic pain including but not limited to pharmacological therapy, physical therapy and interventional pain procedures for chronic pain 5. average baseline pain rating of 60 mm on the visual analog scale in the primary region of pain 6. in the opinion of the investigator, the subject is psychologically appropriate for the implantation for an active implantable medical device 7. subject is able to provide written informed consent exclusion criteria: 1. female subject of childbearing potential is pregnant/nursing, plans to become pregnant or is unwilling to use approved birth control 2. escalating or changing pain condition within the past month as evidenced by investigator examination 3. subject has had corticosteroid therapy at an intended site of stimulation within the past 30 days 4. subject has had radiofrequency treatment of an intended target dorsal root ganglion within the past 3 months 5. subject currently has an active implantable device including implanted cardioverter defibrillator, pacemaker, spinal cord stimulator or intrathecal drug pump 6. subject is unable to operate the device 7. subjects currently has an active infection 8. subject has, in the opinion of the investigator, a medical comorbidity that contraindicates placement of an active medical device 9. subject has participated in another clinical investigation within 30 days that may confound the outcomes of the current study as determined by the investigator
effects of pain on driving performance and cognition.

Conditions: Chronic Pain

Summary: it has been suggested that cognitive functioning is impaired in chronic pain patients. since most of these pain patients engage in daily activities including driving, it was hypothezised that they may have an increased risk of becoming involved in traffic accidents.

most chronic pain patients engage in daily activities including driving. driving a car is a complex task requiring mental alertness and a variety of cognitive functions such as perception, attention, learning, memory and decision making.several studies have demonstrated cognitive impairments on laboratory tasks in patients with chronic pain, particularly on measures assessing attentional capacity, processing speed and psychomotor speed. these findings suggest that car driving performance might be impaired, and that chronic pain patients may therefore have an increased traffic accident risk. unfortunately, no studies have investigated the impact of chronic pain on actual driving ability. the present study was designed to investigate the effects of chronic pain on actual driving performance during normal traffic. in addition to the on-the-road driving test, psychomotor, and memory tests measuring driving-related skills were conducted in the laboratory. moreover, effects of pain on an attentional capacity test were tested using event-related potentials.

Eligibility criteria:
inclusion criteria: age driving licence driving experience normal vision right-handed fluently dutch speaking exclusion criteria: psychological or physical disorder drug or alcohol abuse psychotropic medication use excessive smoking, drinking

Keywords: driving, chronic pain, attention
study of egfr-tki to asymptomatic brain metastases of nsclc

Conditions: Asymptomatic Brain Metastases of Non Small Cell Lung Cancer

Summary: the purpose of this study is to determine whether egfr-tki can control the development of intracranial lesions in non small cell lung cancer patients with asymptomatic brain metastases, and the difference in progression free survival between exon 19 and exon 21 mutations.

a open, positive control of phase ii clinical trials, divided into selection period, treatment period and follow-up period , comply with the standard set of participants signed a written informed consent, according to different divided into 19 patients with egfr mutations outside show son mutation group) and 21 extra show mutations, and according to the ecog physical status, age, previous systemic treatments such as hierarchical analysis, regular follow-up and to assess efficacy, life care and safety.

Eligibility criteria:
inclusion criteria: 1. at the age of 18 -70 years old, male or female 2. the non-small cell lung cancer diagnosed by histopathology 3. detected by arms to confirm that the egfr sensitive mutant patients 4. the existence of mri diagnosis of intracranial metastatic head enhancement, and the presence of imaging evaluating lesions (according to recist1.1) 5. have not received prior treatment of intracranial metastases, including radiotherapy, gamma knife, chemotherapy drugs 6. no brain metastasis symptoms, including, increased intracranial pressure, no vomiting, ignoring the papillary edema, no headache, without hemiplegia, ignore things not clear, without epilepsy 7. ps:0 or 1 8. the expected survival time 3 months \&gt; 9. patients signed informed consent voluntarily exclusion criteria: 1. 4 weeks before entering the group received operation or operation, the wound has not healed completely 2. into group 2 weeks before receiving immune therapy or treatment of traditional chinese medicine 3. serious cardiovascular diseases, including department of internal medicine, uncontrolled hypertension, unstable angina, myocardial infarction history exists within the past june, severe arrhythmia or pericardial effusion 4. serious infection, need intravenous antibiotic, antifungal or antiviral treatment 5. before entering the group 4 weeks participated in any study drug clinical trial 6. there are serious tumor invasion, oppression by the main bronchus or bronchial stenosis or obstruction, superior vena cava syndrome 7. the existence of herniation of brain tumor apoplexy, epilepsy, and frequent 8. suffering from a mental illness, poor compliance 9. the researchers think that do not fit into the group of cases

Keywords: egfr mutations asymptomatic brain metastases egfr-tki erlotinib
root caries excavation with air water/powder prophylaxis device for art restorations

Conditions: Dental Caries Extending Into Dentin; Root Caries

Summary: the main objective of this rct is to compare the efficacy of a powder/water jet prophylaxis device and conventional hand excavation in excavating root surface caries, with regard to restoration survival/success in older adults. the secondary outcome of this rct is to assess the participants' treatment preferences for the received treatment with regard to the procedures involved and in the invasiveness of the procedures carried out during the art restoration.


Eligibility criteria:
inclusion criteria * adults ≥65 years * dentinal root caries lesions with no painful symptomology * can follow instructions for oral hygiene * not dependent for care for their adls. exclusion criteria: * symptomatic carious teeth * non-carious attrition, erosion or abrasion cavities * periodontally compromised teeth with grade 3 mobility, and active signs of infections. * not willing or able to sign informed consent post-hoc exclusion: * participant withdraws consent * medical reasons.

Keywords: root caries elders atraumatic restorative treatment glass-ionomer cement
effectiveness of thyme in the management of clinical symptoms in patients with irritable bowel syndrome

Conditions: Irritable Bowel Syndrome (IBS)

Summary: the goal of this clinical trial is to learn if thyme supplement enhances the effects of a low fodamp diet on reducing clinical symptoms and improving the quality of life of patients with irritable bowel syndrome or not. the main questions it aims to answer are: 1. does consumption of thyme reduce the severity score of clinical symptoms in patients with irritable bowel syndrome? 2. does consumption of thyme increase the quality of life score in patients with irritable bowel syndrome? researchers will compare thyme supplementation with placebo to see if thyme supplement enhances the effects of a low fodamp diet on clinical symptoms and quality of life in patients with irritable bowel syndrome. participants will: 1. receive thyme supplement plus a low fodmap diet or placebo with low fodmap diet for 8 weeks. 2. recorde 3 days (1weekend and 2 workday) dietary recalls at week 4 and week 8 to assess adherence to the low fodmp diet. 3. visit the clinic at the beginning of the study and the end of the study for a check-up and score record


Eligibility criteria:
inclusion criteria: * ages 18-65; * patients with irritable bowel syndrome; * body mass index in the range of 18-25 kg/m2 exclusion criteria: * any organic intestinal disease; * medical history of chronic gastrointestinal and colorectal disease; * any major bowel surgery; * medical history of liver and kidney disorders; * regular use of laxative, anti-diarrhea and anti inflammatory medications.